Q3 2026 revenues were
Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025.
GAAP operating loss was
Quarter ended
- Revenue for the three months ended
September 30, 2026 , totaled$8.6 million , a decrease of 24%, as compared to$11.3 million for the same period of 2025. - 40 Ultramist® systems were sold in Q3 2026, down from 155 in Q3 2025, and from 82 in Q2 2026.
- Ultramist® applicator revenue increased by 2% to
$6.9 million in Q3 2026, as compared to$6.8 million for the same quarter last year. - Gross margin as a percentage of revenue amounted to 77.3% for the three months ended
September 30, 2026 , versus 77.6% for the same period last year. - For the three months ended
September 30, 2026 , operating loss totaled$1.1 million , compared to operating income of$0.9 million in Q3 2025. - Net loss for the third quarter of 2026 was
$1.4 million compared to net income of$9.7 million in the third quarter of 2025. The change was primarily attributable to a$6.1 million non-cash gain on the change in fair value of derivative liabilities and a one-time$5 .0 million gain on the sale of patents, both recognized in the prior-year period and neither of which recurred, and an operating loss of$1.1 million in the current-year period, compared to operating income of$0.9 million in the prior-year period, partially offset by a$1 .5 million decrease in interest expense. - Adjusted EBITDA [1] for the three months ended
September 30, 2026 , was$0.7 million versus Adjusted EBITDA of$3.2 million for the same period last year. - On
September 30, 2026 , the Company had$6.6 million in cash and cash equivalents. This number was affected by the approximately$2.3 million paid out under our sales tax voluntary disclosure agreements during the quarter.
“Q3 was very much the story of the CMS proposed rule,” said CEO
Certain percentages presented in this earnings release are calculated from the underlying whole-dollar amounts and therefore may not recalculate from the rounded numbers used for disclosure purposes.
As previously announced, a business update will occur via conference call on
Telephone access to the call will be available by dialing the following numbers:
Toll Free:1-800-420-1459
Toll/International: 1-203-518-9861
Conference ID:
OR use the link for instant telephone access to the event.
https://viavid.webcasts.com/starthere.jsp?ei=1777177&tp_key=6fc0abed5c
A replay will be made available through
Toll-Free: 1-844-512-2921 or 1-412-317-6671
Replay Access ID: 11162619
[1] This is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” and the reconciliations in this release for further information.
About
Non-GAAP Financial Measures
This press release includes certain financial measures that are not presented in our financial statements prepared in accordance with accounting principles generally accepted in
The Company uses Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA to assess its operating performance. Adjusted EBITDA is Earnings before Interest, Taxes, Depreciation and Amortization adjusted for the change in fair value of derivatives and any significant non-cash or infrequent charges. EBITDA and Adjusted EBITDA should not be considered as alternatives to net (loss) income, as a measure of financial performance or any other performance measure derived in accordance with
EBITDA and Adjusted EBITDA have their limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of the Company’s results as reported under
- Do not reflect every expenditure, future requirements for capital expenditures or contractual commitments.
- Do not reflect all changes in our working capital needs.
- Do not reflect interest expense, or the amount necessary to service our outstanding debt.
- Do not reflect stock-based compensation, which is a recurring expense and an important part of our compensation strategy, income tax expense, or the cost of replacing assets being depreciated and amortized.
As presented in the
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, market acceptance of and demand for Ultramist®, the estimated size of the wound care market, industry trends, regulatory actions that could adversely affect the price of or demand for the Company’s approved products, the Company's ability to comply with the financial and other covenants under its credit agreement with
Contact: investors@sanuwave.com
| SELECTED FINANCIAL DATA FOR THE THREE AND NINE MONTHS ENDED | |||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | 8,579 | $ | 11,270 | $ | 27,937 | $ | 30,657 | |||||||||
| Cost of Revenues | 1,950 | 2,526 | 6,452 | 6,690 | |||||||||||||
| Gross Margin | 6,629 | 8,744 | 21,485 | 23,967 | |||||||||||||
| Gross Margin % | 77.3 | % | 77.6 | % | 76.9 | % | 78.2 | % | |||||||||
| Total operating expenses | 7,701 | 7,841 | 23,961 | 21,025 | |||||||||||||
| Operating (Loss) Income | $ | (1,072 | ) | $ | 903 | $ | (2,476 | ) | $ | 2,942 | |||||||
| Total other (expense) income | (281 | ) | 8,785 | (992 | ) | 1,179 | |||||||||||
| Net (Loss) Income | $ | (1,416 | ) | $ | 9,688 | $ | (3,537 | ) | $ | 4,121 | |||||||
| NON-GAAP ADJUSTED EBITDA | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||
| Net (Loss) Income | $ | (1,416 | ) | $ | 9,688 | $ | (3,537 | ) | $ | 4,121 | |||||
| Non-GAAP Adjustments: | |||||||||||||||
| Interest expense | 276 | 1,795 | 1,340 | 5,643 | |||||||||||
| Depreciation and amortization1 | 341 | 264 | 948 | 757 | |||||||||||
| Income tax expense | 63 | - | 69 | - | |||||||||||
| EBITDA | (736 | ) | 11,747 | (1,180 | ) | 10,521 | |||||||||
| Non-GAAP Adjustments for Adjusted EBITDA: | |||||||||||||||
| Change in fair value of derivative liabilities | - | (6,097 | ) | - | (2,186 | ) | |||||||||
| Other non-cash or infrequent charges and gains: | |||||||||||||||
| Stock-based compensation | 1,480 | 1,397 | 4,622 | 3,513 | |||||||||||
| Loss on extinguishment of debt | - | 477 | - | 477 | |||||||||||
| State & local sales tax2 | (64 | ) | 383 | (258 | ) | 1,088 | |||||||||
| Loss on impairment of assets | - | 196 | 12 | 196 | |||||||||||
| Severance agreement and legal settlement | - | 113 | - | 113 | |||||||||||
| Gain on license and option agreement | - | (5,000 | ) | - | (5,000 | ) | |||||||||
| Sale of excess inventory | 18 | - | (202 | ) | - | ||||||||||
| Adjusted EBITDA | $ | 698 | $ | 3,216 | $ | 2,994 | $ | 8,722 | |||||||
1 Depreciation and amortization excludes amortization of right-of-use (ROU) leases. Prior period amounts have been retroactively revised to conform to this presentation. This change had no effect on previously reported
2 The charges represent a non-recurring state and local sales tax (benefit) expense related to the restatement of prior period financial statements.
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (In thousands, except share data) | |||||||
| ASSETS | |||||||
| Current Assets: | |||||||
| Cash and cash equivalents | $ | 6,569 | $ | 11,959 | |||
| Accounts receivable, net of allowance of | 4,965 | 5,422 | |||||
| Inventory | 6,724 | 5,934 | |||||
| Prepaid expenses and other current assets | 1,002 | 1,312 | |||||
| Secured revolving credit facility debt issuance costs, net | 39 | - | |||||
| Total Current Assets | 19,299 | 24,627 | |||||
| Non-Current Assets: | |||||||
| Property and equipment, net | 2,351 | 1,972 | |||||
| Right of use assets, net | 913 | 390 | |||||
| Intangible assets, net | 2,698 | 3,026 | |||||
| 7,260 | 7,260 | ||||||
| Secured revolving credit facility debt issuance costs, net | - | 68 | |||||
| Total Non-Current Assets | 13,222 | 12,716 | |||||
| Total Assets | $ | 32,521 | $ | 37,343 | |||
| LIABILITIES | |||||||
| Current Liabilities: | |||||||
| Current portion of secured term loan, net of debt issuance costs | $ | 5,660 | $ | 5,638 | |||
| Accounts payable | 3,150 | 3,251 | |||||
| Accrued expenses | 5,877 | 8,382 | |||||
| Secured revolving credit facility | 655 | - | |||||
| Current portion of operating lease liabilities | 9 | 157 | |||||
| Current portion of contract liabilities | 606 | 388 | |||||
| Note payable - insurance premium financing | 420 | - | |||||
| Accrued interest | 10 | 24 | |||||
| Other | 7 | 7 | |||||
| Total Current Liabilities | 16,394 | 17,847 | |||||
| Non-Current Liabilities: | |||||||
| Secured term loan, net of current portion and debt issuance costs | 11,419 | 15,667 | |||||
| Secured revolving credit facility | - | 655 | |||||
| Operating lease liabilities, less current portion | 1,444 | 854 | |||||
| Contract liabilities, less current portion | 414 | 701 | |||||
| Total Non-Current Liabilities | 13,277 | 17,877 | |||||
| Total Liabilities | $ | 29,671 | $ | 35,724 | |||
| STOCKHOLDERS’ EQUITY | |||||||
| Preferred Stock, par value | $ | - | $ | - | |||
| Common stock, par value | 9 | 9 | |||||
| Additional paid-in capital | 249,053 | 244,285 | |||||
| Accumulated deficit | (246,222 | ) | (242,685 | ) | |||
| Accumulated other comprehensive income | 10 | 10 | |||||
| Total Stockholders’ Equity | 2,850 | 1,619 | |||||
| Total Liabilities and Stockholders’ Equity | $ | 32,521 | $ | 37,343 | |||
| CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME | |||||||||||||||
| (In thousands, except share and per share data) | Three Months Ended | Nine Months Ended | |||||||||||||
| 2026 | 2025 (As Restated) | 2026 | 2025 (As Restated) | ||||||||||||
| Revenue | $ | 8,579 | $ | 11,270 | $ | 27,937 | $ | 30,657 | |||||||
| Cost of Revenues | 1,950 | 2,526 | 6,452 | 6,690 | |||||||||||
| Gross Margin | 6,629 | 8,744 | 21,485 | 23,967 | |||||||||||
| Operating Expenses: | |||||||||||||||
| General and administrative | 5,133 | 5,193 | 15,285 | 14,404 | |||||||||||
| Selling and marketing | 1,868 | 2,081 | 6,190 | 5,286 | |||||||||||
| Research and development | 426 | 345 | 1,715 | 747 | |||||||||||
| Depreciation and amortization | 274 | 222 | 771 | 588 | |||||||||||
| Total Operating Expenses | 7,701 | 7,841 | 23,961 | 21,025 | |||||||||||
| Operating (Loss) Income | (1,072 | ) | 903 | (2,476 | ) | 2,942 | |||||||||
| Other (Expense) Income: | |||||||||||||||
| Interest expense | (276 | ) | (1,795 | ) | (1,340 | ) | (5,643 | ) | |||||||
| Loss on extinguishment of debt | - | (477 | ) | - | (477 | ) | |||||||||
| Change in fair value of derivative liabilities | - | 6,097 | - | 2,186 | |||||||||||
| Loss on impairment of assets | - | (196 | ) | (12 | ) | (196 | ) | ||||||||
| Other expense | - | (14 | ) | (125 | ) | (42 | ) | ||||||||
| Other income | (5 | ) | 5,170 | 485 | 5,351 | ||||||||||
| Total Other (Expense) Income, net | (281 | ) | 8,785 | (992 | ) | 1,179 | |||||||||
| Net (Loss) Income Before Income Taxes | (1,353 | ) | 9,688 | (3,468 | ) | 4,121 | |||||||||
| Income tax expense | 63 | - | 69 | - | |||||||||||
| Net (Loss) Income | $ | (1,416 | ) | $ | 9,688 | $ | (3,537 | ) | $ | 4,121 | |||||
| Total Comprehensive (Loss) Income | $ | (1,416 | ) | $ | 9,688 | $ | (3,537 | ) | $ | 4,121 | |||||
| (Loss) Earnings per Share: | |||||||||||||||
| Basic | $ | (0.16 | ) | $ | 1.13 | $ | (0.41 | ) | $ | 0.48 | |||||
| Diluted | $ | (0.16 | ) | $ | 0.39 | $ | (0.41 | ) | $ | 0.21 | |||||
| Weighted average shares outstanding | |||||||||||||||
| Basic | 8,602,309 | 8,571,111 | 8,598,202 | 8,560,174 | |||||||||||
| Diluted | 8,602,309 | 9,140,668 | 8,598,202 | 9,178,144 | |||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (In thousands, except share data) | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||
| Common Stock | |||||||||||||||||||
| Number of Shares Issued and Outstanding | Par Value | Additional Paid- in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total | ||||||||||||||
| Balances as of | 8,602,309 | $ | 9 | $ | 247,574 | $ | (244,806 | ) | $ | 10 | $ | 2,787 | |||||||
| Stock-based compensation | - | - | 1,377 | - | - | 1,377 | |||||||||||||
| Shares granted in lieu of board of director fees | - | - | 103 | - | - | 103 | |||||||||||||
| Net loss | - | - | - | (1,416 | ) | - | (1,416 | ) | |||||||||||
| Balances as of | 8,602,309 | $ | 9 | $ | 249,053 | $ | (246,222 | ) | $ | 10 | $ | 2,850 | |||||||
| Three Months Ended | |||||||||||||||||||
| Common Stock | |||||||||||||||||||
| Number of Shares Issued and Outstanding | Par Value | Additional Paid- in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total | ||||||||||||||
| Balances as of | 8,568,005 | $ | 9 | $ | 241,248 | $ | (260,066 | ) | $ | 10 | $ | (18,799 | ) | ||||||
| Stock-based compensation | - | - | 1,397 | - | - | 1,397 | |||||||||||||
| Stock options exercised | 8,159 | - | 122 | - | - | 122 | |||||||||||||
| Net income (As Restated) | - | - | - | 9,688 | - | 9,688 | |||||||||||||
| Balances as of | 8,576,164 | $ | 9 | $ | 242,767 | $ | (250,378 | ) | $ | 10 | $ | (7,592 | ) | ||||||
| Nine Months Ended | |||||||||||||||||||
| Common Stock | |||||||||||||||||||
| Number of Shares Issued and Outstanding | Par Value | Additional Paid- in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total | ||||||||||||||
| Balances as of | 8,588,876 | $ | 9 | $ | 244,285 | $ | (242,685 | ) | $ | 10 | $ | 1,619 | |||||||
| Stock-based compensation | - | 4,219 | - | - | 4,219 | ||||||||||||||
| Stock options exercised | 5,433 | - | 77 | - | - | 77 | |||||||||||||
| Shares issued for services rendered | 8,000 | - | 164 | - | - | 164 | |||||||||||||
| Shares granted in lieu of board of director fees | - | - | 308 | - | - | 308 | |||||||||||||
| Net loss | - | - | - | (3,537 | ) | - | (3,537 | ) | |||||||||||
| Balances as of | 8,602,309 | $ | 9 | $ | 249,053 | $ | (246,222 | ) | $ | 10 | $ | 2,850 | |||||||
| Nine Months Ended | |||||||||||||||||||
| Common Stock | |||||||||||||||||||
| Number of Shares Issued and Outstanding | Par Value | Additional Paid- in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total | ||||||||||||||
| Balances as of | 8,543,686 | $ | 9 | $ | 238,685 | $ | (254,499 | ) | $ | 10 | $ | (15,795 | ) | ||||||
| Stock-based compensation | 4,787 | - | 3,630 | - | - | 3,630 | |||||||||||||
| Stock options exercised | 25,167 | - | 375 | - | - | $ | 375 | ||||||||||||
| Shares granted in lieu of board of director fees | 2,524 | - | 77 | - | - | 77 | |||||||||||||
| Net income (As Restated) | - | - | - | 4,121 | - | 4,121 | |||||||||||||
| Balances as of | 8,576,164 | $ | 9 | $ | 242,767 | $ | (250,378 | ) | $ | 10 | $ | (7,592 | ) | ||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| Nine Months Ended | |||||||
| (in thousands) | 2026 | 2025 (As Restated) | |||||
| Cash Flows - Operating Activities: | |||||||
| Net (loss) income | $ | (3,537 | ) | $ | 4,121 | ||
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities | |||||||
| Stock-based compensation | 4,622 | 3,513 | |||||
| Depreciation and amortization | 948 | 634 | |||||
| Amortization of right-of-use assets | 95 | 268 | |||||
| Provision for credit losses | 664 | 112 | |||||
| Amortization of debt issuance and debt discounts | 116 | 1,416 | |||||
| Write-off of inventory | 69 | - | |||||
| Loss on disposal and impairment of assets | 18 | 210 | |||||
| Loss on extinguishment of debt | - | 477 | |||||
| Change in fair value of derivative liabilities | - | (2,186 | ) | ||||
| Gain on sale of patents | - | (5,000 | ) | ||||
| Gain on lease modification | - | (7 | ) | ||||
| Proceeds from tenant improvement funds | - | 586 | |||||
| Changes in operating assets and liabilities | |||||||
| Accounts receivable | (206 | ) | (1,387 | ) | |||
| Inventory | (859 | ) | (2,665 | ) | |||
| Prepaid expenses and other assets | 815 | (1,009 | ) | ||||
| Accounts payable | (77 | ) | 264 | ||||
| Accrued expenses and contract liabilities | (2,519 | ) | 1,289 | ||||
| Operating leases | (178 | ) | (79 | ) | |||
| Net Cash Flows (Used in) Provided by Operating Activities | (29 | ) | 557 | ||||
| Cash Flows - Investing Activities: | |||||||
| Purchase of property and equipment | (593 | ) | (1,846 | ) | |||
| Investment in software development | (218 | ) | - | ||||
| Proceeds from sale of patents | - | 5,000 | |||||
| Net Cash Flows (Used in) Provided by Investing Activities | (811 | ) | 3,154 | ||||
| Cash Flows - Financing Activities: | |||||||
| Repayment of principal secured term loan | (4,313 | ) | - | ||||
| Repayment of insurance premium financing note payable | (315 | ) | - | ||||
| Proceeds from exercises of stock options | 77 | 359 | |||||
| Payment of note payable | - | (27,747 | ) | ||||
| Proceeds from secured term loan | - | 23,000 | |||||
| Proceeds from secured revolving credit facility | - | 655 | |||||
| Payment of debt issuance costs | - | (371 | ) | ||||
| Payments of principal on finance lease and extinguishment of lease liability | - | (242 | ) | ||||
| Net Cash Flows Used in Financing Activities | (4,550 | ) | (4,346 | ) | |||
| Net Change in Cash During Period | (5,390 | ) | (635 | ) | |||
| Cash at Beginning of Period | 11,959 | 10,237 | |||||
| Cash at End of Period | $ | 6,569 | $ | 9,602 | |||
| Supplemental Information: | |||||||
| Cash paid for interest | $ | 1,511 | $ | 3,291 | |||
| Cash paid for taxes | $ | 87 | $ | - | |||
| Non-cash Investing and Financing Activities: | |||||||
| Stock options granted in lieu of cash bonus | 69 | 117 | |||||
| Right-of-use assets obtained in exchange for lease liabilities | 619 | 430 | |||||
| Insurance premiums financed through note payable | 466 | - | |||||
| Transfer of deposits to property and equipment | 192 | - | |||||
| Purchases of property and equipment in accounts payable and accrued liabilities | 59 | - | |||||
| Capitalize interest into senior secured debt | - | 549 | |||||
| Shares granted in lieu of board of director fees | - | 77 | |||||
| Lease liabilities reduced upon lease modification | - | 99 | |||||
| RSUs granted in exchange for services | - | 10 | |||||
Source: